Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: A European multicentre nested case-control study

BMJ Open

Volumn 6, Issue 3, 2016, Pages

  Ciani, Oriana ^a,b   Arendsen, Erik ^c   Romancik, Martin ^d   Lunik, Richard ^c   Costantini, Elisabetta ^e   Di Biase, Manuel ^e   Morgia, Giuseppe ^f   Fragalà, Eugenia ^f   Roman, Tomaskin ^g   Bernat, Marian ^h   Guazzoni, Giorgio ⁱ   Tarricone, Rosanna ^a   Lazzeri, Massimo ⁱ  

^a BOCCONI UNIVERSITY   (Italy)

^b UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^c Diaconessenhuis Maatschap Urologie ^*  (Slovakia)

^d UNIVERSITY HOSPITAL BRATISLAVA   (Slovakia)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF CATANIA   (Italy)

^g Martinska Fakultna Nemocnica   (Slovakia)

^h Urologicka Klinika   (Slovakia)

ⁱ HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CHONDROITIN SULFATE; HYALURONIC ACID; PROBIOTIC AGENT;

ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRANBERRY; DYSPAREUNIA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; QUALITY OF LIFE; RECURRENT INFECTION; URINARY TRACT INFECTION; CASE CONTROL STUDY; CLINICAL TRIAL; COMBINATION DRUG THERAPY; EUROPE; FACTUAL DATABASE; INTRAVESICAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; CASE-CONTROL STUDIES; CHONDROITIN SULFATES; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; HUMANS; HYALURONIC ACID; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84962433758     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-009669     Document Type: Article

References (40)

1. Laupland KB, Ross T, Pitout JD, et al. Community-onset urinary tract infections: a population-based assessment. Infection 2007;35:150-3.
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):5S-13S.
3. Foxman B, Barlow R, D'Arcy H, et al. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000;10:509-15.
4. Hooton TM, Scholes D, Hughes JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996;335:468-74.
5. Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653-60.
6. Sen A. Recurrent cystitis in non-pregnant women. Clin Evid 2008;07:801.
7. Ikaheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996;22:91-9.
8. Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990;80:331-3.
9. Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151:1194-205.
10. Albert X, Huertas I, Pereiró II, et al. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;(3):CD001209.
11. Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract infection: the 'costs of resignation'. Clin Drug Investig 2013;33:255-61.
12. Renard J, Ballarini S, Mascarenhas T, et al. Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther 2015;4:125-35.
13. Bermingham SL, Ashe JF. Systematic review of the impact of urinary tract infections on health-related quality of life. BJU Int 2012;110(Pt C):E830-6.
14. Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ 2013;346:f3140.
15. Arya LA, Northington GM, Asfaw T, et al. Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int 2012;110:247-51.
16. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
17. Grabe M, Bartoletti R, Bjerklund Johansen T, et al. Guidelines on urological infections. Eur Assoc Urol 2015. http://uroweb.org/wpcontent/uploads/19-Urological-infections-LR2.pdf
18. Shepherd AK, Pottinger PS. Management of urinary tract infections in the era of increasing antimicrobial resistance. Med Clin North Am 2013;97:737-57, xii.
19. Schito GC, Naber KG, Botto H, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009;34:407-13.
20. Lazzeri M, Montorsi F. The therapeutic challenge of "chronic cystitis": search well, work together, and gain results. Eur Urol 2011;60:78-80.
21. De Vita D, Antell H, Giordano S. Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent bacterial cystitis in adult women: a meta-analysis. Int Urogynecol J 2013;24:545-52.
22. Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans-a review. Neurourol Urodyn 2013;32:9-18.
23. Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160-4.
24. EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208.
25. Lamers LM, McDonnell J, Stalmeier PF, et al. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006;15:1121-32.
26. Scalone L, Cortesi PA, Ciampichini R, et al. Italian population-based values of EQ-5D health states. Value Health 2013;16:814-22.
27. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108.
28. Constantinides C, Manousakas T, Nikolopoulos P, et al. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 2004;93:1262-6.
29. Damiano R, Quarto G, Bava I, et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 2011;59:645-51.
30. De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J 2012;23:1707-13.
31. Lipovac M, Kurz C, Reithmayr F, et al. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007;96:192-5.
32. Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis 2007;44:769-74.
33. Little P, Merriman R, Turner S, et al. Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010;340:b5633.
34. Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002;113(Suppl 1A):14S-19S.
35. Hooton TM, Levy SB. Antimicrobial resistance: a plan of action for community practice. Am Fam Physician 2001;63:1087-98.
36. Fauci AS, Marston LD. The perpetual challenge of antimicrobial resistance. JAMA 2014;311:1853-4.
37. Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations-1.pdf
38. [No authors listed]. Antimicrobial resistance: in terms politicians understand. Lancet 2014;384:2173.
39. Woolhouse M, Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature 2014;509:555-7.
40. Geoghegan-Quinn M. Funding for antimicrobial resistance research in Europe. Lancet 2014;384:1186.